Akili (AKLI) EPS (Basic) : $-0.76 (TTM As of Dec. 2023)

View and export this data going back to 2022. Start your Free Trial

What is Akili EPS (Basic)?

Akili's basic earnings per share (Basic EPS) for the three months ended in Dec. 2023 was $-0.14. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.76.

Akili's EPS (Diluted) for the three months ended in Dec. 2023 was $-0.14. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.76.

Akili's EPS without NRI for the three months ended in Dec. 2023 was $-0.14. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Dec. 2023 was -0.80.

During the past 3 years, the average EPS without NRI Growth Rate was -34.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 5 years, Akili's highest 3-Year average EPS without NRI Growth Rate was -34.10% per year. The lowest was -120.20% per year. And the median was -77.15% per year.

Akili EPS (Basic) Historical Data

The historical data trend for Akili's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Akili EPS (Basic) Chart

Akili Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

EPS (Basic)

-0.27

-0.33

-1.63

-0.64

-0.76

Akili Quarterly Data
	Dec19	Sep20	Dec20	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
EPS (Basic)	Get a 7-Day Free Trial								-0.22	-0.27	-0.15	-0.20	-0.14

Akili EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

Akili's Basic EPS for the fiscal year that ended in Dec. 2023 is calculated as

Basic EPS (A: Dec. 2023 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(-59.493	-	0)	/	78.197
	=	-0.76

Akili's Basic EPS for the quarter that ended in Dec. 2023 is calculated as

Basic EPS (Q: Dec. 2023 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(-11.147	-	0)	/	78.340
	=	-0.14

EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.76

Akili (NAS:AKLI) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Akili EPS (Basic) Related Terms

Thank you for viewing the detailed overview of Akili's EPS (Basic) provided by GuruFocus.com. Please click on the following links to see related term pages.

Akili (AKLI) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Akili Inc (NAS:AKLI) » Definitions » EPS (Basic)

Comparable Companies

Traded in Other Exchanges

AKLI:Mexico

Address

125 Broad Street, Fifth Floor, Boston, MA, USA, 02110

Website

https://www.akiliinteractive.com

Akili Inc is a digital medicine company pioneering the development of cognitive treatments through game-changing technologies.

Executives

Jacqueline Studer	officer: Chief Legal Officer	IDEXX LABORATORIES, ONE IDEXX DRIVE, WESTBROOK ME 04092
Matthew Franklin	officer: See Remarks	AKILI INTERACTIVE LABS, INC., 125 BROAD STREET, 5TH FLOOR, BOSTON MA 02110
Martucci Walter Edward Ii	director, officer: Chief Executive Officer	AKILI INTERACTIVE LABS, INC., 125 BROAD STREET 5TH FLOOR, BOSTON MA 02110
Santosh Shanbhag	officer: Chief Financial Officer	AKILI INTERACTIVE LABS, INC., 125 BROAD STREET 5TH FLOOR, BOSTON MA 02110
Chamath Palihapitiya	director, 10 percent owner	THE SOCIAL-CAPITAL PARTNERSHIP, L.L.C., 506 SANTA CRUZ AVENUE, SUITE 300, MENLO PARK CA 94025
Mary Hentges	director	C/O SHOTSPOTTER, INC., 7979 GATEWAY BLVD., STE. 210, NEWARK CA 94560
Tls Beta Pte. Ltd.	10 percent owner	60B ORCHARD ROAD #06-18, THE ATRIUM@ORCHARD, SINGAPORE U0 238891
Temasek Holdings (private) Ltd	10 percent owner	60B ORCHARD ROAD #06-18 TOWER 2, THE ATRIUM@ORCHARD, SINGAPORE U0 238891
Fullerton Management Pte Ltd	10 percent owner	60B ORCHARD ROAD #06-18 TOWER 2, THE ATRIUM@ORCHARD, SINGAPORE U0 238891
Anil Jina	officer: Chief Medical Officer	AKILI INTERACTIVE LABS, INC., 125 BROAD STREET 5TH FLOOR, BOSTON MA 02110
Temasek Life Sciences Private Ltd	10 percent owner	60B ORCHARD ROAD #06-18, THE ATRIUM@ORCHARD, SINGAPORE U0 238891
Jonathan David	officer: Chief Product Officer	AKILI INTERACTIVE LABS, INC., 125 BROAD STREET 5TH FLOOR, BOSTON MA 02110
Kenneth Ehlert	director	AKILI INTERACTIVE LABS, INC., 125 BROAD STREET, 5TH FLOOR, BOSTON MA 02110
Christine Lemke	director	AKILI INTERACTIVE LABS, INC., 125 BROAD STREET, 5TH FLOOR, BOSTON MA 02110
Adam Gazzaley	director	AKILI INTERACTIVE LABS, INC., 125 BROAD STREET, 5TH FLOOR, BOSTON MA 02110